No Data
No Data
Sinovac Biotech Embraces Post-Pandemic Challenges
Sinovac Biotech 2H Sales $307.9 >SVA
Sinovac Biotech 2H Sales $307.9 >SVA
Express News | Investing in Xingmeng Biotech, Kexon Biotech enters a new field of innovative antibody drugs
Seasonal Influenza Global Clinical Trials Review 2024 Featuring GSK, Novartis, Johnson & Johnson, Novavax, CSL, Sinovac Biotech, Moderna, and Sanofi, Among Others
Sernova Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
Express News | Kexon Biotech: Clinical Study on Adsorbed Tetanus Vaccine Reveals Mysteries
No Data